Ocular Therapeutix Inc (OCUL) - Total Assets
Based on the latest financial reports, Ocular Therapeutix Inc (OCUL) holds total assets worth $732.53 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore OCUL operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Ocular Therapeutix Inc - Total Assets Trend (2012–2025)
This chart illustrates how Ocular Therapeutix Inc's total assets have evolved over time, based on quarterly financial data. See Ocular Therapeutix Inc book value and equity for net asset value and shareholders' equity analysis.
Ocular Therapeutix Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Ocular Therapeutix Inc's total assets of $732.53 Million consist of 96.8% current assets and 3.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 91.2% |
| Accounts Receivable | $30.65 Million | 3.8% |
| Inventory | $3.56 Million | 0.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Ocular Therapeutix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Ocular Therapeutix Inc (OCUL) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ocular Therapeutix Inc's current assets represent 96.8% of total assets in 2025, an increase from 96.0% in 2012.
- Cash Position: Cash and equivalents constituted 91.2% of total assets in 2025, down from 94.3% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 3.8% of total assets.
Ocular Therapeutix Inc Competitors by Total Assets
Key competitors of Ocular Therapeutix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Jinyu Bio-Technology Co Ltd
SHG:600201
|
China | CN¥6.54 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Ocular Therapeutix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.81 | 10.22 | 10.05 |
| Quick Ratio | 14.73 | 10.14 | 10.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $658.31 Million | $349.77 Million | $194.97 Million |
Ocular Therapeutix Inc - Advanced Valuation Insights
This section examines the relationship between Ocular Therapeutix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.63 |
| Latest Market Cap to Assets Ratio | 2.30 |
| Asset Growth Rate (YoY) | 76.5% |
| Total Assets | $808.06 Million |
| Market Capitalization | $1.86 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Ocular Therapeutix Inc's assets at a significant premium (2.30x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Ocular Therapeutix Inc's assets grew by 76.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ocular Therapeutix Inc (2012–2025)
The table below shows the annual total assets of Ocular Therapeutix Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $808.06 Million | +76.46% |
| 2024-12-31 | $457.94 Million | +81.68% |
| 2023-12-31 | $252.06 Million | +68.84% |
| 2022-12-31 | $149.29 Million | -27.14% |
| 2021-12-31 | $204.89 Million | -21.76% |
| 2020-12-31 | $261.86 Million | +232.57% |
| 2019-12-31 | $78.74 Million | +7.80% |
| 2018-12-31 | $73.04 Million | +31.77% |
| 2017-12-31 | $55.43 Million | -26.03% |
| 2016-12-31 | $74.94 Million | -32.06% |
| 2015-12-31 | $110.31 Million | +41.07% |
| 2014-12-31 | $78.19 Million | +308.40% |
| 2013-12-31 | $19.15 Million | -24.28% |
| 2012-12-31 | $25.29 Million | -- |
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as wel… Read more